Seminars in liver disease最新文献_第9页

Novel Biomarkers of AKI in Cirrhosis. 肝硬化AKI的新生物标志物。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-11-01 DOI: 10.1055/a-1954-4136

Adrià Juanola, Ann T Ma, Elisa Pose, Pere Ginès

{"title":"Novel Biomarkers of AKI in Cirrhosis.","authors":"Adrià Juanola, Ann T Ma, Elisa Pose, Pere Ginès","doi":"10.1055/a-1954-4136","DOIUrl":"https://doi.org/10.1055/a-1954-4136","url":null,"abstract":"Acute kidney injury (AKI) is a frequent complication in patients with cirrhosis that is associated with poor outcomes and decreased survival. The definition of AKI in cirrhosis is currently based on changes of serum creatinine levels with respect to baseline values. Differential diagnosis of the causes of AKI is of major relevance, considering that some causes of AKI, such as hepatorenal syndrome, have specific treatment options and different prognosis. Prediction of kidney function recovery and patients' survival is also crucial in this patient population to guide clinical decisions. AKI biomarkers in cirrhosis have emerged as a promising tool for differential diagnosis and prognosis in this situation. There are consistent data showing that some urine biomarkers, particularly neutrophil gelatinase-associated lipocalin, may be useful in daily clinical practice for the differential diagnosis of the cause of AKI in cirrhosis. AKI biomarkers may constitute a useful tool for use in differential diagnosis, prognosis of renal function, and survival in patients with cirrhosis. This review focuses on the current state of knowledge and future perspective of novel biomarkers of AKI in cirrhosis.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 4","pages":"489-500"},"PeriodicalIF":4.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10703395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease. 将三维有机体作为研究非酒精性脂肪肝的模型

IF 5.4 3区医学

Seminars in liver disease Pub Date : 2022-11-01 Epub Date: 2022-08-31 DOI: 10.1055/a-1934-5588

Yujin Park, Deepthi Thadasina, Ifeoluwa Bolujo, Abdulkadir Isidan, Arthur A Cross-Najafi, Kevin Lopez, Ping Li, Andrew M Dahlem, Lindsey Kennedy, Keisaku Sato, Heather Francis, Gianfranco Alpini, Wenjun Zhang, Burcin Ekser

{"title":"Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease.","authors":"Yujin Park, Deepthi Thadasina, Ifeoluwa Bolujo, Abdulkadir Isidan, Arthur A Cross-Najafi, Kevin Lopez, Ping Li, Andrew M Dahlem, Lindsey Kennedy, Keisaku Sato, Heather Francis, Gianfranco Alpini, Wenjun Zhang, Burcin Ekser","doi":"10.1055/a-1934-5588","DOIUrl":"10.1055/a-1934-5588","url":null,"abstract":"Despite the rising prevalence of nonalcoholic fatty liver disease (NAFLD), the underlying disease pathophysiology remains unclear. There is a great need for an efficient and reliable \"human\" in vitro model to study NAFLD and the progression to nonalcoholic steatohepatitis (NASH), which will soon become the leading indication for liver transplantation. Here, we review the recent developments in the use of three-dimensional (3D) liver organoids as a model to study NAFLD and NASH pathophysiology and possible treatments. Various techniques that are currently used to make liver organoids are discussed, such as the use of induced pluripotent stem cells versus primary cell lines and human versus murine cells. Moreover, methods for inducing lipid droplet accumulation and fibrosis to model NAFLD are explored. Finally, the limitations specific to the 3D organoid model for NAFLD/NASH are reviewed, highlighting the need for further development of multilineage models to include hepatic nonparenchymal cells and immune cells. The ultimate goal is to be able to accurately recapitulate the complex liver microenvironment in which NAFLD develops and progresses to NASH.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 4","pages":"423-433"},"PeriodicalIF":5.4,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10729312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma. 肝细胞癌姑息治疗和支持治疗的早期实施。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-11-01 DOI: 10.1055/a-1946-5592

Cameron Gofton, Meera Agar, Jacob George

引用次数: 0

From a Single Cell to a Whole Human Liver: Disease Modeling and Transplantation. 从单细胞到整个人类肝脏：疾病建模与移植。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2022-11-01 Epub Date: 2022-08-31 DOI: 10.1055/a-1934-5404

Takashi Motomura, Lanuza A P Faccioli, Ricardo Diaz-Aragon, Zehra N Kocas-Kilicarslan, Nils Haep, Rodrigo M Florentino, Sriram Amirneni, Zeliha Cetin, Bhaavna S Peri, Kazutoyo Morita, Alina Ostrowska, Kazuki Takeishi, Alejandro Soto-Gutierrez, Edgar N Tafaleng

{"title":"From a Single Cell to a Whole Human Liver: Disease Modeling and Transplantation.","authors":"Takashi Motomura, Lanuza A P Faccioli, Ricardo Diaz-Aragon, Zehra N Kocas-Kilicarslan, Nils Haep, Rodrigo M Florentino, Sriram Amirneni, Zeliha Cetin, Bhaavna S Peri, Kazutoyo Morita, Alina Ostrowska, Kazuki Takeishi, Alejandro Soto-Gutierrez, Edgar N Tafaleng","doi":"10.1055/a-1934-5404","DOIUrl":"10.1055/a-1934-5404","url":null,"abstract":"Although the underlying cause may vary across countries and demographic groups, liver disease is a major cause of morbidity and mortality globally. Orthotopic liver transplantation is the only definitive treatment for liver failure but is limited by the lack of donor livers. The development of drugs that prevent the progression of liver disease and the generation of alternative liver constructs for transplantation could help alleviate the burden of liver disease. Bioengineered livers containing human induced pluripotent stem cell (iPSC)-derived liver cells are being utilized to study liver disease and to identify and test potential therapeutics. Moreover, bioengineered livers containing pig hepatocytes and endothelial cells have been shown to function and survive after transplantation into pig models of liver failure, providing preclinical evidence toward future clinical applications. Finally, bioengineered livers containing human iPSC-derived liver cells have been shown to function and survive after transplantation in rodents but require considerable optimization and testing prior to clinical use. In conclusion, bioengineered livers have emerged as a suitable tool for modeling liver diseases and as a promising alternative graft for clinical transplantation. The integration of novel technologies and techniques for the assembly and analysis of bioengineered livers will undoubtedly expand future applications in basic research and clinical transplantation.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 4","pages":"413-422"},"PeriodicalIF":4.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/c7/10-1055-a-1934-5404.PMC9718640.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9343064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shared Mechanisms between Cardiovascular Disease and NAFLD. 心血管疾病和非酒精性脂肪肝之间的共同机制。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2022-11-01 Epub Date: 2022-08-25 DOI: 10.1055/a-1930-6658

Daniel Q Huang, Michael Downes, Ronald M Evans, Joseph L Witztum, Christopher K Glass, Rohit Loomba

引用次数: 0

Unraveling the Complexity of Liver Disease One Cell at a Time. 一次一个细胞地揭示肝病的复杂性。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-08-01 DOI: 10.1055/s-0042-1755272

Jawairia Atif, Cornelia Thoeni, Gary D Bader, Ian D McGilvray, Sonya A MacParland

引用次数: 3

Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD. 肝细胞代谢损伤促进NAFLD和AALD的进展。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-08-01 DOI: 10.1055/s-0042-1755316

Raquel Carvalho-Gontijo, Cuijuan Han, Lei Zhang, Vivian Zhang, Mojgan Hosseini, Kristin Mekeel, Bernd Schnabl, Rohit Loomba, Michael Karin, David A Brenner, Tatiana Kisseleva

{"title":"Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD.","authors":"Raquel Carvalho-Gontijo, Cuijuan Han, Lei Zhang, Vivian Zhang, Mojgan Hosseini, Kristin Mekeel, Bernd Schnabl, Rohit Loomba, Michael Karin, David A Brenner, Tatiana Kisseleva","doi":"10.1055/s-0042-1755316","DOIUrl":"https://doi.org/10.1055/s-0042-1755316","url":null,"abstract":"Nonalcoholic liver disease is a component of metabolic syndrome associated with obesity, insulin resistance, and hyperlipidemia. Excessive alcohol consumption may accelerate the progression of steatosis, steatohepatitis, and fibrosis. While simple steatosis is considered a benign condition, nonalcoholic steatohepatitis with inflammation and fibrosis may progress to cirrhosis, liver failure, and hepatocellular cancer. Studies in rodent experimental models and primary cell cultures have demonstrated several common cellular and molecular mechanisms in the pathogenesis and regression of liver fibrosis. Chronic injury and death of hepatocytes cause the recruitment of myeloid cells, secretion of inflammatory and fibrogenic cytokines, and activation of myofibroblasts, resulting in liver fibrosis. In this review, we discuss the role of metabolically injured hepatocytes in the pathogenesis of nonalcoholic steatohepatitis and alcohol-associated liver disease. Specifically, the role of chemokine production and de novo lipogenesis in the development of steatotic hepatocytes and the pathways of steatosis regulation are discussed.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 3","pages":"233-249"},"PeriodicalIF":4.2,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662188/pdf/nihms-1844224.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9481703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update. 非酒精性脂肪性肝炎药物开发管道:最新进展

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-06-16 DOI: 10.1055/a-1877-9656

N. Chew, C. Ng, Emily Truong, M. Noureddin, K. Kowdley

引用次数: 18

Cellular Homeostasis and Repair in the Biliary Tree. 胆道树的细胞稳态和修复。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-06-07 DOI: 10.1055/a-1869-7714

Wei Wang, Dongfeng Chen, Jun Wang, Liangzhi Wen

引用次数: 2

EARLY DIAGNOSIS AND PREVENTION OF INFECTIONS IN CIRRHOSIS. 肝硬化感染的早期诊断和预防。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-06-07 DOI: 10.1055/a-1869-7607

A. Kulkarni, M. Premkumar, J. Arab, Karan Kumar, Mithun Sharma, N. Reddy, N. Padaki, R. Reddy

{"title":"EARLY DIAGNOSIS AND PREVENTION OF INFECTIONS IN CIRRHOSIS.","authors":"A. Kulkarni, M. Premkumar, J. Arab, Karan Kumar, Mithun Sharma, N. Reddy, N. Padaki, R. Reddy","doi":"10.1055/a-1869-7607","DOIUrl":"https://doi.org/10.1055/a-1869-7607","url":null,"abstract":"Cirrhosis is a risk factor for infections. Majority of hospital admissions in patients with cirrhosis are due to infections. Sepsis is an immunological response to an infectious process that leads to end-organ dysfunction and death. Preventing infections may avoid the downstream complications and early diagnosis of infections may improve the outcomes. In this review, we discuss the pathogenesis, diagnosis, and biomarkers of infection, as well as incremental preventive strategies for infections and sepsis and consequent organ failures in cirrhosis. Strategies for primary prevention include reducing gut translocation by selective intestinal decontamination, avoiding unnecessary proton pump inhibitors' use, appropriate use of beta-blockers and vaccinations for viral diseases, including coronavirus disease-2019. Secondary prevention includes early diagnosis and timely and judicious use of antibiotics to prevent organ dysfunction. Organ failure support constitutes tertiary intervention in cirrhosis. In conclusion, infections in cirrhosis are potentially preventable with appropriate care strategies to then enable to improve outcomes.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"40 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77732300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13